Fig. 5From: Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumabOccurrence of irAEs and AEs of any grade (a), of Grade 3–4 (b), and irAEs/AEs LTD (c) across the different body mass index categories. irAE immune-related adverse event, AE non immune-related adverse event, LTD leading to treatment discontinuationBack to article page